I am an Associate Professor of Biochemistry and one of the Coordinators of the Biology Area at FAPESP and CNPq. I lead the Laboratory of Neuroproteomics since 2014, when I returned from Germany after a period of 2 years as Principal Investigator at LMU - Ludwig Maximilians Universität Muenchen (12-14). My expertise is mainly in mass spectrometry-based proteomics (shotgun proteomics) and systems biology in silico, employed to clinical and pre-clinical models for psychiatric disorders. I am a Biologist (03), with a PhD in Biochemistry (08) obtained at Unicamp. My postdoctoral experience was at the Max Planck Institute of Psychiatry in Germany (08-10) and at the University of Cambridge in the United Kingdom (10-12), where I also led the Mass Spectrometry Unit at the Cambridge Center for Neuropsychiatric Research (CCNR). At the same time, I was a consultant for Psynova Neurotech Ltd. I was Elected Affiliated Member of the Brazilian Academy of Sciences (17-21), Affiliated Member of the Academy of Sciences of the State of São Paulo (19-23) and Head of the Department of Biochemistry and Tissue Biology (22-24). I am also a founding member of BrProt and board member of BrMass. I was elected to the board of the Human Proteome Organization (15-17) and I have been a member of the Human Brain Proteome Project Steering Committee since 2015 and chair in 2023. I am an Associate Editor of npj Schizophrenia (Nature), member of the editorial board of 8 other scientific journals and a permanent editor of a book series entitled "Proteomics, Metabolomics, Interactomics and Systems Biology" by Springer-Nature. I gave more than 60 oral presentations at international conferences, including Plenary Speaker, Keynote Speaker and Chair. H39 (ISI) and H49 (Scholar) with more then 9100 citations (Scholar). (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Depression due to inflammation |
| Depresión por inflamación |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Major Depressive Disorder (MDD) stands as a significant contributor to worldwide disability, impacting approximately 20% of people at some point in their lives. MDD is a complex condition characterized by a diverse array of symptoms and its current treatment is mostly pharmacological. The limited response of MDD patients to antidepressants is the main clinical issue for medication adheren…
This equipment will enable the establishment of a lipidomic platform for the study of brain diseases, in particular psychiatric disorders. This equipment will be combined with the mass spectrometer also funded by FAPESP (2014 / 10068-4). (AU)
Schizophrenia is among the most disabling diseases of humankind, affecting 1% of the world's population (in Brazil, almost 2.5 million people are affected). One of the biggest hurdles faced by most patients is the poor efficacy of current antipsychotic medication. This stems from the lack of understanding of schizophrenia's pathobiology and the lack of biomarkers and biological mechanisms…
Schizophrenia is a severe mental disorder that affects 0.7% of the worldwide population. The interactions between genetic and environment factors seem to be responsible for alterations in neurodevelopment, resulting in the manifestation of schizophrenia in late adolescence to early adulthood. The pathophysiology of schizophrenia is highly complex and involves several neurotransmission sys…
Rapidly, SARS-CoV-2 viral infections became pandemic, leading several countries to a state of public calamity. Using a non-hypothesis driven methodology based on proteomics and metabolomics, the present project aims to identify the molecular mechanisms involved in SARS-CoV-2 infection in macrophage and pulmonary epithelium cultures as well as cultured neurons and astrocytes. We will also …
(Only some records are available in English at this moment)
Major depressive disorder (MDD) is a complex and multifactorial disease, which involves genetic, environmental and social factors, and affects approximately 280 million people worldwide, being one of the most disabling diseases in the world. Currently, treatment for the disease consists of drugs that modulate monoaminergic systems. However, approximately 30% of patients are refractory, wh…
Depression is considered the fourth leading cause of premature death and disability. This disease is commonly associated with depressed mood, anhedonia, changes in behavior and appetite, and reduced productivity at work. The main treatment is the administration of antidepressants from different classes. However, it is observed that up to 30% of patients using antidepressants do not experi…
Schizophrenia is a severe and debilitating mental disorder characterized by positive, negative, and cognitive symptoms with a prevalence of approximately 1% of the world's population. It has a complex etiology involving a multifactorial interaction between genetic and environmental risk factors. While the exact causes of schizophrenia are still unclear, there is growing evidence that neur…
(Only some records are available in English at this moment)
Neurodegenerative diseases (NDs) are characterized by neuronal loss and may be accompanied by protein abnormalities. These diseases do not yet have efficient treatments and tend to increase with population aging, making them important targets for study. Microglia are essential for maintaining homeostasis in the central nervous system (CNS), as well as actively participating in various phy…
(Only some records are available in English at this moment)
Psychiatric disorders like schizophrenia and depression have common underlying mechanisms including glutamatergic dysfunction, neuroinflammation, mitochondrial dysfunction, and their crosstalk. Impairment in autophagy, a cell survival process essential for cellular, energy and metabolic homeostasis, has been linked to these alterations. A promising drug candidate for psychiatric disorders…
Antipsychotics are a group of drugs used mainly to treat psychotic disorders like schizophrenia. Generally, they act as dopamine receptor agonists but also can affect adrenergic, serotonergic, cholinergic, and histamine receptors, which promote the management of a range of symptoms. Clozapine is considered one of the most effective antipsychotics. However, despite its benefits, clozapine …
Schizophrenia is a debilitating mental disorder, which affects approximately 1% of the world population, bringing a significant social and economic burden. Schizophrenia is a multifactorial disease associated with several gene/protein alterations that are highly influenced by environmental factors. Disease symptoms generally manifest in young adults when the neurodevelopment is at its end…
The brain is the most cholesterol-rich organ, accounting for 25% of the total cholesterol present in the human body, and is essential for synaptic transmission. Within the brain, myelin contains the majority of cholesterol, representing 70%, with the other 30% being present in the membranes of neurons and glial cells. Disturbances in cholesterol metabolism and levels are a risk factor for…
(Only some records are available in English at this moment)
| 3 / 3 | Ongoing grants |
| 8 / 6 | Completed research grants |
| 5 / 5 | Ongoing scholarships in Brazil |
| 42 / 37 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 7 / 7 | Completed scholarships abroad |
| 66 / 59 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID